Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 3/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2601622 | 0.92 | KCNH2 (0.44) | KCNH2GSK3BKDM4EHPGDALDH1A1 | |
| SCHEMBL2825321 | 0.91 | KCNH2 (0.45) | KCNH2GSK3BKDM4EHPGDALDH1A1 | |
| SCHEMBL2825319 | 0.89 | KCNH2 (0.46) | KCNH2GSK3BKDM4EHPGDALDH1A1 | |
| SCHEMBL23298401 | 0.88 | CYP3A4 (0.46) | KCNH2GSK3BKDM4EHPGDALDH1A1 | |
| SCHEMBL13520173 | 0.88 | TOP2A (0.41) | KCNH2GSK3BKDM4EHPGDALDH1A1 | |
| SCHEMBL2108874 | 0.87 | KDM4E (0.49) | KCNH2GSK3BKDM4EHPGDALDH1A1 | |
| SCHEMBL14368791 | 0.87 | KCNH2 (0.44) | KCNH2GSK3BKDM4EHPGDALDH1A1 | |
| SCHEMBL14940560 | 0.86 | KCNH2 (0.49) | KCNH2GSK3BKDM4EHPGDALDH1A1 | |
| Acetic Acid SCHEMBL28945125 | 0.83 | KCNH2 (0.58) | KCNH2GSK3BKDM4EHPGDALDH1A1 | |
| SCHEMBL116421 | 0.83 | KCNH2 (0.60) | KCNH2GSK3BKDM4EHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658183-B2 | Antimicrobial parenteral formulation | Taigen Biotechnology Company, Ltd. (TW) | 2014-02-25 | — | — | US | disclosed |
| US-8658183-B2 | Antimicrobial parenteral formulation | Taigen Biotechnology Company, Ltd. (TW) | 2014-02-25 | — | — | US | disclosed |
| US-8211909-B2 | Treatment of antibiotic-resistant bacteria infection | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-07-03 | — | — | US | disclosed |
| US-8211909-B2 | Treatment of antibiotic-resistant bacteria infection | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-07-03 | — | — | US | disclosed |
| US-20120157492-A1 | ANTIBIOTIC DRUG | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-06-21 | — | — | US | disclosed |
| US-20120157492-A1 | ANTIBIOTIC DRUG | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-06-21 | — | — | US | disclosed |
| US-8158798-B2 | Coupling process for preparing quinolone intermediates | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-04-17 | — | — | US | disclosed |
| US-8158798-B2 | Coupling process for preparing quinolone intermediates | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-04-17 | — | — | US | disclosed |
| US-8039485-B2 | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | WARNER CHILCOTT COMPANY, LLC (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039485-B2 | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | WARNER CHILCOTT COMPANY, LLC (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2007110836-A1 | A HYDRIDE REDUCTION PROCESS FOR PREPARING QUINOLONE INTERMEDIATES | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20070232650-A1 | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | THE PROCTER & GAMBLE COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070232650-A1 | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | THE PROCTER & GAMBLE COMPANY | 2007-10-04 | — | — | US | disclosed |
| WO-2007110834-A2 | MALATE SALTS, AND POLYMORPHS OF (3S,5S)-7-[3-AMINO-5-METHYL-PIPERIDINYL]-1-CYCLOPROPYL-1,4-DIHYDRO-8-METHOXY-4-OXO-3-QUINOLINECARBOXYLIC ACID | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20070232804-A1 | Coupling process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232804-A1 | Coupling process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232806-A1 | Hydride reduction process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2007110835-A2 | A COUPLING PROCESS FOR PREPARING QUINOLONE INTERMEDIATES | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | WO | disclosed |
| US-7179805-B2 | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-20 | — | — | US | disclosed |
| US-7179805-B2 | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232804-A1 | Coupling process for preparing quinolone intermediates | CYP3A4, CYP4B1, CYP4X1 | KCNH2 1111/4885GSK3B 3457/4885KDM4E 1624/4885 |
| US-20120157492-A1 | ANTIBIOTIC DRUG | MAL2, ME1, ACE | KCNH2 1385/4885GSK3B 4467/4885KDM4E 943/4885 |
| US-20070232650-A1 | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | SLC25A11, MDH2, MDH1 | KCNH2 2469/4885GSK3B 3708/4885KDM4E 1950/4885 |
| US-20070232806-A1 | Hydride reduction process for preparing quinolone intermediates | NQO1, NQO2, POR | KCNH2 704/4885GSK3B 2436/4885KDM4E 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.